{
    "title": "112_s2067",
    "content": "The \"Safe, Efficient, and Transparent Medical Device Approval Act\" or the \"SET Device Act\" establishes a schedule and regulations for medical device approval, including modifications to the de novo application process. Congress amended the Federal Food, Drug, and Cosmetic Act to reclassify devices or require premarket approval. The FDA has not yet complied with this mandate. The de novo process allows the FDA to down-classify devices with no predicates from class III to class I or II if they are deemed low to moderate risk. The de novo process allows the FDA to reclassify devices from class III to class I or II if they are low to moderate risk. However, the process has faced challenges with review times increasing between 2005 and 2009. A modified de novo process has been recommended to address these issues. The FDA can reclassify devices from class III to class I or II using the de novo process, which has faced challenges with review times increasing between 2005 and 2009. A modified de novo process has been recommended to address these issues. The Secretary of Health and Human Services must establish a schedule for devices remaining in class III within 120 days of the Act's enactment. Within 18 months, final regulations and special controls must be issued for these devices. The Secretary of Health and Human Services must establish special controls for class II devices under section 513(a)(1)(B) of the Act within 18 months of the Act's enactment. Modification of de novo application process. Modification of de novo application process. Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act is amended to allow for the classification of a device under certain criteria if it has not been classified before. The person submitting the device may recommend a classification for it. The person submitting a device may request classification under specific criteria if there is no legally marketed device for comparison. The Secretary will classify the device based on provided information and may recommend a classification. Initial draft proposals for special controls should be included in the request. The draft proposal includes special controls necessary for safety and effectiveness, along with general controls, to provide assurance. The Secretary may decline classification if a legally marketed device can be used for comparison or if the device is not low-moderate risk. The draft proposal includes special controls for safety and effectiveness, along with general controls. The Secretary may decline classification if a legally marketed device can be used for comparison or if the device is not low-moderate risk. A study on the effectiveness of the review pathway under the Federal Food, Drug, and Cosmetic Act must be completed within 2 years of the Act's enactment. The Food, Drug, and Cosmetic Act is amended to include a request under paragraph (2) or after a response to."
}